Thermo Fisher Scientific reported first‑quarter 2026 results that beat consensus estimates, with revenue of $11.01 billion, up 6 % year‑over‑year, and adjusted earnings per share of $5.44, exceeding the $5.25 consensus by $0.19 per share.
The company’s top‑line growth was driven largely by a 3‑percentage‑point lift from acquisitions, while organic revenue grew only 1 %. Adjusted operating income rose 6 % to $2.40 billion, and the adjusted operating margin fell slightly to 21.8 % from 21.9 % in the same quarter a year earlier, reflecting the impact of tariffs, foreign‑exchange headwinds and an unfavorable product mix.
Thermo Fisher raised its full‑year 2026 revenue outlook to $47.3 billion–$48.1 billion, up from the previous $46.3 billion–$47.2 billion, and lifted its adjusted EPS guidance to $24.64–$25.12, reflecting the contribution of the $8.88 billion Clario acquisition completed on March 24 2026.
Segment analysis shows that revenue from Analytical Instruments was flat and Specialty Diagnostics declined, while the Clario acquisition added $30 million in revenue and $0.01 in adjusted EPS. The company’s management noted that “We delivered a strong start to the year, reflecting excellent execution by our team, as we leveraged the PPI Business System to drive operational excellence and enable our customers' success.” They also added, “We continued to make great progress executing our strategy, further strengthening our capabilities with the addition of Clario.”
Investors reacted cautiously to the results, focusing on the modest organic growth and the weakness in key segments. Management emphasized that the raised guidance signals confidence in continued demand and the positive impact of the Clario integration, while acknowledging that tariffs, foreign‑exchange headwinds and an unfavorable mix are ongoing headwinds that will require continued focus on cost discipline and product mix optimization.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.